Alkermes to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 10:25 a.m. ET and the Piper Sandler 36th Annual Healthcare Conference on December 4 at 4:00 p.m. ET.

The presentations will be accessible via live webcasts on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.

News Market Reaction

-0.37%

1 alert

-0.37% News Effect

On the day this news was published, ALKS declined 0.37%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.

7^th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)

Piper Sandler 36^th Annual Healthcare Conference
Date/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-upcoming-investor-conferences-302315492.html

SOURCE Alkermes plc

FAQ

When is Alkermes (ALKS) presenting at the Evercore ISI HealthCONx Conference in December 2024?

Alkermes (ALKS) is presenting at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:25 a.m. ET (3:25 p.m. GMT).

What time is Alkermes (ALKS) presenting at the Piper Sandler Healthcare Conference in December 2024?

Alkermes (ALKS) is presenting at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 4:00 p.m. ET (9:00 p.m. GMT).

How long will Alkermes (ALKS) investor conference webcasts be available for viewing?

The webcasts of Alkermes' investor conference presentations will be archived and available for viewing for 14 days on the company's website under the Investors tab.

What therapeutic areas does Alkermes (ALKS) focus on as of 2024?

Alkermes focuses on neuroscience, developing treatments for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and has clinical candidates for neurological disorders including narcolepsy and idiopathic hypersomnia.